A5013439509- Blood Coagulation and Thrombosis Mechanisms
- Maternal and fetal healthcare
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular Issues in Pregnancy
- Pregnancy and preeclampsia studies
- Platelet Disorders and Treatments
- Cardiac Structural Anomalies and Repair
- Hemophilia Treatment and Research
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- COVID-19 Clinical Research Studies
- Maternal and Perinatal Health Interventions
- Trauma and Emergency Care Studies
- Acute Myocardial Infarction Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Uterine Myomas and Treatments
- Innovations in Medical Education
- COVID-19 and healthcare impacts
- Streptococcal Infections and Treatments
- Emergency and Acute Care Studies
- Acute Ischemic Stroke Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood groups and transfusion
Auckland City Hospital
2013-2022
University of Auckland
2003-2019
University of Minnesota System
2019
Auckland District Health Board
2013-2016
Queen's University
2016
Faculty of 1000 (United States)
2016
University of Oklahoma Health Sciences Center
2015
Monash University
2011
Duke University Hospital
2011
Duke Medical Center
2011
von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans. Accurate and timely diagnosis presents numerous challenges.These evidence-based guidelines of American Society Hematology (ASH), International on Thrombosis Haemostasis (ISTH), National Hemophilia Foundation (NHF), World Federation (WFH) are intended to support patients, clinicians, other health care professionals their decisions about VWD diagnosis.ASH, ISTH, NHF, WFH established a multidisciplinary...
This is the Executive Summary of updated guidelines developed by Society Obstetric Medicine Australia and New Zealand for management hypertensive diseases pregnancy. They address a number challenging areas including definition severe hypertension, use automated blood pressure monitors, non‐proteinuric pre‐eclampsia measuring proteinuria. Controversial issues are addressed such as treatment hypertension other significant manifestations pre‐eclampsia, role expectant in remote from term,...
Background Postpartum hemorrhage ( PPH ) remains one of the leading causes maternal morbidity and mortality worldwide, although lack a precise definition precludes accurate data absolute prevalence . Study Design Methods An international expert panel in obstetrics, gynecology, hematology, transfusion, anesthesiology undertook comprehensive review literature. At meeting N ovember 2011, agreed on severe that would identify those women who were at high risk adverse clinical outcomes. Results...
Participants All women with 2009 H1N1 influenza who were pregnant or recently post partum and admitted to an intensive care unit in Australia New Zealand between 1 June 31 August 2009.
Abstract New oral anticoagulants ( NOAC ) are becoming available as alternatives to warfarin prevent systemic embolism in patients with non‐valvular atrial fibrillation and for the treatment prevention of venous thromboembolism. An in‐depth understanding their pharmacology is invaluable appropriate prescription optimal management receiving these drugs should unexpected complications (such bleeding) occur, or patient requires urgent surgery. The Australasian S ociety T hrombosis H aemostasis...
Venous thromboembolism (VTE) in pregnancy and the postpartum is an important cause of maternal morbidity mortality; yet, there are few robust data from clinical trials to inform approach diagnosis management. Failure investigate symptoms suggestive pulmonary embolism (PE) a consistent finding death enquiries, should not be relied on exclude or diagnose VTE. In this consensus statement, we present our recommendations for management acute deep venous thrombosis (DVT) PE. All women with...
Objective Estimate the incidence of placenta accreta and describe risk factors, clinical practice perinatal outcomes. Design Case–control study. Setting Sites in Australia New Zealand with at least 50 births per year. Participants Cases were women giving birth (≥20 weeks or fetus ≥400 g) who diagnosed by antenatal imaging, operation pathology specimens between 2010 2012. Controls two immediately prior to a case. A total 295 cases included 570 controls. Methods Data collected using...
In Brief Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such fetal growth restriction, preeclampsia, abruption, and loss. An inherited thrombophilia is only one many factors that lead to development these diseases unlikely be the unique factor should drive management in subsequent pregnancies. The paucity evidence for benefit, coupled with small potential harm, suggests low molecular weight heparin considered an experimental drug...
Through the Australian and New Zealand Haemostasis Registry, we report on experience with recombinant activated factor VII (rFVIIa) in obstetric patients.The role of rFVIIa for off-label indications, including trauma, cardiac surgery, severe postpartum hemorrhage, remains controversial. The Registry established by Monash University Melbourne, Australia monitors use across Zealand. purpose this study was to summarize data all hemorrhage patients treated at participating hospitals between...
Recombinant activated factor VII (rFVIIa) is emerging as a novel therapy for the treatment of life or fertility‐threatening post‐partum haemorrhage (PPH) unresponsive to standard that in some cases may prevent need peripartum hysterectomy. The level evidence date use rFVIIa PPH limited case reports and series with one nonrandomised study. No high‐quality randomised controlled trials have been published at this stage, precluding quality systematic review. Guidelines non‐obstetric haemorrhage,...
Pulmonary embolism (PE) has not been accounted for as a cause of death contributing to cause-specific mortality in global reports.We analyzed PE-related by focusing on the latest year available each member state World Health Organization (WHO) database, which provides age-sex-specific aggregated data transmitted national authorities underlying death. deaths were defined International Classification Diseases, Tenth Revision codes acute PE or nonfatal manifestations venous thromboembolism...
Pregnancy is a risk factor for venous thromboembolism (VTE), an important cause of maternal morbidity and mortality. Although there 4-5-fold increased compared to that nonpregnant women the same age, absolute low at no more than two episodes VTE per 1000 pregnancies. There uncertainty about which require thromboprophylaxis during pregnancy or postpartum because lack data from appropriate clinical trials. For this reason, recommendations prophylaxis should be made only after explaining...